Oral hydralazine in patients with pulmonary vascular disease secondary to congenital heart disease.
Two patients with pulmonary vascular obstructive disease secondary to congenital heart disease were evaluated hemodynamically before and during oral hydralazine therapy. Both patients were assessed postoperatively and had no significant residual shunts. Pulmonary vascular resistance failed to decrease, and an increase in pulmonary arterial pressure occurred because of increased cardiac output secondary to systemic arteriolar dilatation. These responses were sufficiently consistent to warrant a warning against the use of oral hydralazine except under controlled conditions in patients with secondary pulmonary vascular obstructive disease.
D000284:Administration, Oral; D002302:Cardiac Output; D002648:Child; D002675:Child, Preschool; D005260:Female; D006330:Heart Defects, Congenital / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use*; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D008297:Male; D011660:Pulmonary Heart Disease / Q000188:drug therapy* / Q000209:etiology; D011669:Pulmonary Wedge Pressure; D014655:Vascular Resistance
D006830:Hydralazine